Therapeutic advances in cardiovascular disease may have far-reaching public benefits. Bone morphogenetic proteins (BMPs) are emerging as essential regulators of the vasculature, important in disorders such as arteriovenous malformations (AVMs) and diabetic vasculopathy. Our data show that endothelial BMP4 activity causes a sequential induction of two BMP inhibitors, Matrix Gla Protein (MGP) and Crossveinless-2 (Cv2). MGP inhibits BMP4, and when deficient, allows the emergence of stem cell markers in the endothelium, vascular calcification, and AVMs. Deficiency of Cv2 leads to an abnormal and thickened endothelium, without the increase in stem cell markers. Our data suggest a 2-step model where MGP regulates proliferation and stem cell characteristics in vascular progenitor cells, and Cv2 regulates proliferation and maturation of committed ECs. In this 2-step model, we hypothesize that BMP4 and MGP regulate the size of the vascular progenitor pool, whereas BMP9 and Cv2 regulate the size of the committed EC pool. Thus, enhanced BMP4 activity or decreased MGP would allow for osteogenesis in the multipotent progenitor cells leading to vascular calcification. Both MGP and Cv2 may play important roles in the regulation of diabetic microvascular abnormalities and AVMs. We hypothesize that by manipulating MGP and Cv2, we will be able to inhibit the vascular abnormalities in which these inhibitors play a role.
Specific Aim 1 will test the validity of a 2-step model of EC lineage differentiation in vitro and in vivo. The model predicts that elevating the level of MGP will limit excessive endothelial growth resulting from Cv2 deficiency.
Specific Aim 2 will determine the contribution of MGP and Cv2 to the formation of AVMs in a mouse model of hereditary hemorrhagic telangiectasia (HHT). Our model predicts that increasing BMP inhibition through MGP or Cv2 will limit the signs of HHT.
Specific Aim 3 will determine the mechanism by which BMP inhibition could regulate diabetic vasculopathy. MGP and Cv2 are predicted to be stage-specific BMP inhibitors, and inadequate BMP inhibition would allow for vascular pathology in the aorta and the microvasculature as modeled by the diabetic Ins2Akita/+ mouse. If successful, the obtained information may translate into strategies for using BMP inhibitors in treating vascular disease.

Public Health Relevance

Our studies are relevant to the treatment of disease of the heart and vessels such as hardening of the arteries, which is common in patients with diabetes, and hereditary hemorrhagic telangiectasia, a hereditary disease. Our studies focus on factors called bone morphogenetic proteins and their inhibitors, which are important in regulating the heart and vessels. Understanding how these factors work may lead to new strategies for prevention and treatment.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Srinivas, Pothur R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Internal Medicine/Medicine
Schools of Medicine
Los Angeles
United States
Zip Code
Jumabay, Medet; Abdmaulen, Raushan; Ly, Albert et al. (2014) Pluripotent stem cells derived from mouse and human white mature adipocytes. Stem Cells Transl Med 3:161-71
Guo, Yina; Chen, Ting-Hsuan; Zeng, Xingjuan et al. (2014) Branching patterns emerge in a mathematical model of the dynamics of lung development. J Physiol 592:313-24
Yao, Yucheng; Jumabay, Medet; Ly, Albert et al. (2013) A role for the endothelium in vascular calcification. Circ Res 113:495-504
Mungrue, Imran N; Zhao, Peng; Yao, Yucheng et al. (2011) Abcc6 deficiency causes increased infarct size and apoptosis in a mouse cardiac ischemia-reperfusion model. Arterioscler Thromb Vasc Biol 31:2806-12
Yao, Yucheng; Watson, Andrew D; Ji, Sheng et al. (2009) Heat shock protein 70 enhances vascular bone morphogenetic protein-4 signaling by binding matrix Gla protein. Circ Res 105:575-84
Shao, Esther S; Lin, Laura; Yao, Yucheng et al. (2009) Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 114:2197-206
Yao, Yucheng; Shao, Esther S; Jumabay, Medet et al. (2008) High-density lipoproteins affect endothelial BMP-signaling by modulating expression of the activin-like kinase receptor 1 and 2. Arterioscler Thromb Vasc Biol 28:2266-74
Yao, Yucheng; Nowak, Sarah; Yochelis, Arik et al. (2007) Matrix GLA protein, an inhibitory morphogen in pulmonary vascular development. J Biol Chem 282:30131-42
Bostrom, Kristina (2007) Osteopontin, a missing link in PDGF-induced smooth muscle cell migration. Cardiovasc Res 75:634-5
Yao, Yucheng; Zebboudj, Amina F; Torres, Alejandra et al. (2007) Activin-like kinase receptor 1 (ALK1) in atherosclerotic lesions and vascular mesenchymal cells. Cardiovasc Res 74:279-89

Showing the most recent 10 out of 11 publications